Zhaoke Ophthalmology Reports H1 2025 Revenue of RMB 15.8 Million and Submits NDAs for Three Core Drug Candidates

On August 28, Zhaoke Ophthalmology announced its interim results for 2025, with revenue of approximately RMB 15.8 million in the first half of 2025. Excluding the one-time licensing income of RMB 33.5 million recognized in the same period last year under product license agreements, the company’s revenue from drugs and products in the first half of this year amounted to approximately RMB 15.1 million, representing a slight decline compared to RMB 15.6 million in the same period of 2024.

In the first half of 2025, Zhaoke’s three core candidate drugs—atropine sulfate eye drops, cyclosporine ophthalmic gel, and bevacizumab intravitreal injection—entered the New Drug Application (NDA) stage. Furthermore, Zhaoke expects to achieve the significant milestone of commercializing a cumulative total of 12 drug products by the end of 2026.